v3.26.1
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Series C Redeemable Convertible Preferred Stock
Series B-1 Redeemable Convertible Preferred Stock
Series B Redeemable Convertible Preferred Stock
Series A-1 Redeemable Convertible Preferred Stock
Series A Redeemable Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at Dec. 31, 2024   $ 224,992 $ 11,981 $ 51,094 $ 15,963 $ 4,793        
Balance, Shares at Dec. 31, 2024   147,325,527 4,622,496 45,010,383 14,946,844 5,000,000        
Balance at Dec. 31, 2024 $ (193,628)             $ 5,577 $ 163 $ (199,368)
Balance, Shares at Dec. 31, 2024             761,276      
Stock-based compensation expense 212             212    
Issuance of common stock from exercises of stock options 5             5    
Issuance of common stock from exercises of stock options, Shares             884      
Unrealized loss on available-for-sale investments (78)               (78)  
Net Income (Loss) (22,340)                 (22,340)
Balance at Mar. 31, 2025   $ 224,992 $ 11,981 $ 51,094 $ 15,963 $ 4,793        
Balance, Shares at Mar. 31, 2025   147,325,527 4,622,496 45,010,383 14,946,844 5,000,000        
Balance at Mar. 31, 2025 (215,829)             5,794 85 (221,708)
Balance, Shares at Mar. 31, 2025             762,160      
Balance at Dec. 31, 2024   $ 224,992 $ 11,981 $ 51,094 $ 15,963 $ 4,793        
Balance, Shares at Dec. 31, 2024   147,325,527 4,622,496 45,010,383 14,946,844 5,000,000        
Balance at Dec. 31, 2024 (193,628)             5,577 163 (199,368)
Balance, Shares at Dec. 31, 2024             761,276      
Unrealized loss on available-for-sale investments (113)                  
Net Income (Loss) (52,185)                  
Balance at Jun. 30, 2025   $ 224,992 $ 11,981 $ 51,094 $ 15,963 $ 4,793        
Balance, Shares at Jun. 30, 2025   147,325,527 4,622,496 45,010,383 14,946,844 5,000,000        
Balance at Jun. 30, 2025 (245,062)             6,441 50 (251,553)
Balance, Shares at Jun. 30, 2025             789,241      
Balance at Mar. 31, 2025   $ 224,992 $ 11,981 $ 51,094 $ 15,963 $ 4,793        
Balance, Shares at Mar. 31, 2025   147,325,527 4,622,496 45,010,383 14,946,844 5,000,000        
Balance at Mar. 31, 2025 (215,829)             5,794 85 (221,708)
Balance, Shares at Mar. 31, 2025             762,160      
Stock-based compensation expense 148             148    
Issuance of common stock from exercises of stock options 3             3    
Issuance of common stock from exercises of stock options, Shares             474      
Issuance of common stock to NeuroSolis, Inc. 496             496    
Issuance of common stock to NeuroSolis, Inc., Shares             26,607      
Unrealized loss on available-for-sale investments (35)               (35)  
Net Income (Loss) (29,845)                 (29,845)
Balance at Jun. 30, 2025   $ 224,992 $ 11,981 $ 51,094 $ 15,963 $ 4,793        
Balance, Shares at Jun. 30, 2025   147,325,527 4,622,496 45,010,383 14,946,844 5,000,000        
Balance at Jun. 30, 2025 (245,062)             6,441 50 (251,553)
Balance, Shares at Jun. 30, 2025             789,241      
Balance at Dec. 31, 2025 458,372           $ 5 819,115 (228) (360,520)
Balance, Shares at Dec. 31, 2025             44,024,088      
Stock-based compensation expense 9,636             9,636    
Issuance of common stock from exercises of stock options 1             1    
Issuance of common stock from exercises of stock options, Shares             205      
Settlement of restricted stock units 0             0    
Settlement of restricted stock units, Shares             1,139,648      
Purchases of common stock under the Employee Stock Purchase Plan 650             650    
Purchases of common stock under the Employee Stock Purchase Plan, Shares             44,981      
Payment of employee tax obligations related to vesting of restricted stock units (7,502)             (7,502)    
Unrealized loss on available-for-sale investments (655)               (655)  
Net Income (Loss) (60,668)                 (60,668)
Balance at Mar. 31, 2026 399,834           $ 5 821,900 (883) (421,188)
Balance, Shares at Mar. 31, 2026             45,208,922      
Balance at Dec. 31, 2025 $ 458,372           $ 5 819,115 (228) (360,520)
Balance, Shares at Dec. 31, 2025             44,024,088      
Issuance of common stock from exercises of stock options, Shares 10,747                  
Unrealized loss on available-for-sale investments $ (716)                  
Net Income (Loss) (120,860)                  
Balance at Jun. 30, 2026 348,299           $ 5 830,618 (944) (481,380)
Balance, Shares at Jun. 30, 2026             45,436,867      
Balance at Mar. 31, 2026 399,834           $ 5 821,900 (883) (421,188)
Balance, Shares at Mar. 31, 2026             45,208,922      
Stock-based compensation expense 8,626             8,626    
Issuance of common stock from exercises of stock options 92             92    
Issuance of common stock from exercises of stock options, Shares             10,542      
Settlement of restricted stock units 0                  
Settlement of restricted stock units, Shares             217,403      
Unrealized loss on available-for-sale investments (61)               (61)  
Net Income (Loss) (60,192)                 (60,192)
Balance at Jun. 30, 2026 $ 348,299           $ 5 $ 830,618 $ (944) $ (481,380)
Balance, Shares at Jun. 30, 2026             45,436,867